The association between pretransplant body composition and posttransplant outcomes in renal transplant recipients is unclear. It was hypothesized that in hemodialysis patients higher muscle mass (represented by higher pretransplant serum creatinine level) and larger body size (represented by higher pretransplant body mass index [BMI]) are associated with better posttransplant outcomes.
Introduction
An obesity paradox has been consistently observed in dialysis patients, but conflicting data have been published about the association of pretransplant body size and weight with posttransplant graft and patient survival in renal transplant recipients. Early studies had reported poorer kidney transplant outcomes in obese dialysis patients (1) (2) (3) (4) , mainly because of cardiovascular (5) and infectious complications such as surgical wound infections (6) . However, more recent studies have reported that weight change before transplantation did not correlate with graft loss and death after kidney transplantation (7) , although obese recipients develop diabetes mellitus or surgical complications more frequently (6,8 -11) . Many transplant centers exclude or suspend obese patients with a body mass index (BMI) Ͼ30 or Ͼ35 kg/m 2 from the transplant waitlist and refer them for weight reduction strategies such as bariatric surgery (12) . However, clinical trials of bariatric surgery in populations without kidney disease indicate comparable weight loss but higher postsurgery mortality (13) . In a recent report, BMI Ն 35 kg/m 2 was the third most common reason to deny transplant waitlisting and affecting 10% of potential renal transplant candidates (14) . Because the long-term consequences of obesity after transplantation remain unclear (5, 15) , it is important to address the potential association between pretransplant body composition and posttransplant outcomes.
Previous studies of obesity in kidney transplant recipients used solely BMI to define obesity (1-4), but BMI is unable to differentiate between adiposity and muscle mass (16) . Reduced muscle mass (sarcopenia) is a predictor of mortality in dialysis patients (17) . To better characterize patients' nutritional status, additional parameters such as waist circumference or serum creatinine have been suggested (17) (18) (19) (20) (21) (22) . Indeed, in maintenance dialysis patients with minimal residual function under steady state, serum creatinine may better reflect muscle mass compared with BMI (17,19 -22) . However, the association of pretransplant serum creatinine in dialysis patients with various posttransplant outcomes has not been studied in kidney transplant recipients. We hypothesized that higher pretransplant BMI and larger muscle mass as represented by higher pretransplant serum creatinine concentration during the weeks immediately before the kidney transplantation are associated with better posttransplant patient and graft survival.
Materials and Methods

Patients
We 
Clinical and Demographic Measures
The creation of the national DaVita MHD patient cohort has been described previously (22) (23) (24) (25) (26) . To minimize measurement variability, all repeated measures for each patient during the last calendar quarter before kidney transplantation (i.e., over a 13-week or 3-month interval) were averaged and the quarterly means were used. In addition to quarterly laboratory values, posthemodialysis weight (to calculate 3-month averaged BMI) was also recorded using up to 39 recoded posthemodialysis weight measurements from the thrice-weekly MHD treatment.
We divided pretransplant BMI into six a priori selected categories: Ͻ20, 20 to Ͻ22, 22 to Ͻ25, 25 to Ͻ30, 30 to Ͻ35, and Ն35 kg/m 2 . These increments were most consistent with our previous study (27) . The pretransplant serum creatinine levels, usually measured at least once monthly immediately before a mid-week hemodialysis treatment, were divided into seven a priori selected categories: Ͻ4, 4 to Ͻ6, 6 to Ͻ8, 8 to Ͻ10, 10 to Ͻ12, 12 to Ͻ14, and Ն14 mg/dl. Dialysis vintage was defined as the duration of time between the first day of dialysis treatment and the day of kidney transplantation.
Laboratory Measures
Blood samples were drawn using uniform techniques in all of the DaVita dialysis clinics and were transported to the DaVita Laboratory in Deland, Florida, typically within 24 hours. All laboratory values were measured by automated and standardized methods in the DaVita Laboratory. Most laboratory values were measured monthly, including serum creatinine, urea, albumin, calcium, phosphorus, bicarbonate, and total iron binding capacity. Serum ferritin and intact PTH were measured at least quarterly. Hemoglobin was measured weekly to biweekly in most patients. Most blood samples were collected predialysis, with the exception of the postdialysis serum urea nitrogen to calculate urea kinetics. Kt/V (single pool) was calculated using urea kinetic modeling equations as described elsewhere (25) . Albumin-corrected calcium was calculated by subtracting 0.8 mg/dl for each 1 g/dl of serum albumin below 4.0 g/dl (28) .
Statistical Analyses
Survival analyses included Cox proportional hazards regression models using variables recorded during the last pretransplant calendar quarter. Graft failure was defined as initiation of dialysis treatment or retransplantation. For each analysis, three models were examined based on the level of multivariate adjustment: Sensitivity analyses were performed using time-averaged (time before transplant up to 5 years) and baseline data. Sporadically missing covariate data were imputed by the last value carried forward method. Proportional hazard assumption was tested using log(Ϫlog) against survival plots. Analyses were carried out with SAS, version 9.1 (SAS Institute Inc., Cary, NC).
Results
The 2 ) probably due to wrong height values (n ϭ 768), subjects who interrupted MHD treatment before transplantation (n ϭ 838), and those with outlier age (n ϭ 57), 10,090 MHD patients remain in the study population. These patients were followed until death, graft failure, loss of follow-up, or survival until June 30, 2007 , as recorded in the SRTR database. Among the 10,090 observed renal transplant recipients, there were 727 deaths (7.2%), including 150 patients who died after graft failure, and 759 graft failures (7.5%) irrespective of subsequent deaths. The median follow-up time was 832 days, with a maximum of 2185 days. Table 1 compares the demographic, clinical, and pretransplant laboratory characteristics of the 10,090 transplanted and 128,668 nontransplanted MHD patients in the 5-year DaVita cohort. Both groups had the same mean BMI; however, transplanted patients were 14 years younger and less likely to be diabetic, African American, or to have Medicare as their primary insurance. With the exception of serum bicarbonate and blood white blood cell count, transplanted patients had significantly different laboratory values, mostly indicative of better nutritional status.
As shown in Table 2 , 83% of the transplanted patients were in the normal, overweight, or mildly obese BMI categories (i.e., BMI in the 20-to 35-kg/m 2 range). Crude mortality was the lowest in the highest BMI category (Ͼ35 kg/m 2 ). However, the highest (Ͼ35 kg/m 2 ) and the lowest BMI groups (Ͻ20 kg/m 2 ) exhibited slightly more graft failures (9%) compared with the other BMI groups (7% to 8%) over the 6 years of observation. As shown in Table 3 the highest serum creatinine category (Ͼ14 mg/dl), reflecting the largest muscle mass, was associated with the lowest crude mortality (4%), whereas the lowest serum creatinine category (Ͻ4 mg/dl) was associated with the highest crude graft failure rate (13%).
The associations of pretransplant 3-month-averaged serum creatinine and BMI categories with the posttransplant risk of death, graft failure, or the composite of graft failure or death are shown in Figures 1 and 2 and Table 4 (as well  as Tables e1 through e6 in the Appendix). Using the group with pretransplant BMI in the 22-to Ͻ25-kg/m 2 range as the reference, the case-mix-adjusted 6-year death risk in renal transplant recipients with a low BMI (Ͻ20 kg/m 2 ) was 67% higher (hazard ratio [HR]: 1.67 [1.22 to 2.27], P ϭ 0.001) ( Figure 1A ), although after additional adjustment for MICS and transplant-related variables this association mitigated. High pretransplant BMI (Ն35 kg/m 2 ) was associated with graft failure in the unadjusted model, but the association did not persist after multivariate adjustment ( Figure 1B) . Similar trends were observed with the composite of graft failure and death ( Figure 1C ). Sensitivity analyses after adjusting for ten pre-existing comorbid states including eight cardiovascular diseases, chronic obstructive pulmonary disease, and cancer resulted in similar findings (data not shown).
Compared with patients with pretransplant 3-monthaveraged serum creatinine of 8 to Ͻ10 mg/dl (reference), the patient groups with higher pretransplant serum creatinine (12 to Ͻ14 and Ն14 mg/dl) had 44% (HR: 0.56 [0.43 to 0.73]) and 54% (HR: 0.46 [0.33 to 0.64]) lower case-mixadjusted death risk, respectively (P Ͻ 0.001). Importantly, patients with serum creatinine of 4 to Ͻ6 mg/dl had a 51% higher (HR: 1.51 [1.11 to 2.05], P ϭ 0.01) case-mix-adjusted death risk (Figure 2A ). These differences maintained even after adjustment for MICS and transplant data (Figure 2A) . The lowest pretransplant creatinine groups had 2.6 times higher (HR: 2.64 [1.10 to 6.34]) graft failure risk (P ϭ 0.03) ( Figure 2B ). Dialysis vintage was the confounder that contributed the most to the difference observed between unadjusted and multivariate-adjusted associations. Similar associations were also found for the composite outcome ( Figure 2C ). In particular, compared with the reference serum creatinine group (8 to Ͻ10 mg/dl), there was a 2.2-fold increased risk of combined graft loss or death with the lowest pretransplant serum creatinine (HR: 2.16 [1.08 to 4.35], P ϭ 0.03), whereas the highest pretransplant serum creatinine exhibited 22% lower risk of posttransplant adverse outcomes (HR: 0.78 [0.59 to 1.02], P ϭ 0.06). Every 1-mg/dl increase of pretransplant serum creatinine was associated with 6% lower combined risk of death or graft failure when adjusted for BMI and other covariates (HR: 0.94 [0.91 to 0.97], P Ͻ 0.001) ( Table 4 ). Sensitivity analyses after adjusting for ten pre-existing comorbid states found similar results (data not shown).
We also categorized renal transplant recipients into four groups on the basis of their pretransplant BMI and serum creatinine levels being above or below the median value of these measures (26 kg/m 2 and 10.5 mg/dl, respectively), leading to two concordant (high/high and low/low) and two discordant (high/low and low/high) groups (see Table e7 in the Appendix). The posttransplant death HRs are shown in Figure 3 . Compared with the low-creatinine and low-BMI groups (reference), the groups with high creatinine and high BMI had 34% lower adjusted death risk (HR: 0.66 [0.49 to 0.88], P Ͻ 0.01) (Figure 3 and Table e8 ).
Discussion
In 10,090 kidney transplant recipients with comprehensive pretransplant data as MHD patients who were followed for up to 6 years posttransplantation, low pretransplant BMI (Ͻ22 kg/m 2 ) showed a trend toward higher posttransplant mortality, whereas obesity (BMI Ն 30 kg/ mPrevious reports have described conflicting associations between BMI and various outcomes in kidney transplant recipients. Early studies showed higher risk of postoperative complications (15) and early surgical wound infections (6) in obese patients. Lentine et al. reported higher incidence of cardiovascular (heart failure and atrial fibrillation) and early postoperative complications in obese versus nonobese patients (5). However, others did not find any association between pretransplant BMI and mortality (7-9,30). Chang et al. reported that obesity per se was not associated with poorer kidney transplant outcomes, although it was associated with factors that led to poorer graft and patient survival (31) . Being underweight was associated with late graft failure, mainly because of chronic allograft nephropathy (31) . Moreover, patients with a BMI Ն30 receiving single pediatric kidneys had better death- 886 (9) 1975 (12) 2276 (23) 3246 (32) 1687 (17) 820 (8) Ͻ0.001
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Values in parentheses represent the percent of the HD patients in each BMI category or the crude death rate or crude graft failure rate in the indicated group during the 6 years of observation, as appropriate. PRA is last value before transplant. censored graft survival rates when compared with nonobese patients (32). Zaydfudim et al. reported that pretransplant overweight and obese status did not affect physical quality of life after kidney transplantation (33) . Somewhat contrary to our findings, Meier-Kreische et al. reported U-shaped risk patterns such that high and low BMI were related to increased risk of death and graft failure (34) , and Gore et al. found graded bivariate increases in the risk of delayed graft function, prolonged hospitalization, early graft loss, and graft failure with higher BMI level (35) . However, the former study examined the U.S. Renal Data System database between 1988 and 1997, whereas the latter study used the United Network of Organ Sharing database between 1997 and 1999. During the aforementioned period, the immunosuppressive protocols were different (e.g., no tacrolimus was available). Moreover, the latter cohort was younger and had less diabetic and African-American patients.
Very obese patients are frequently denied transplant waitlisting or are advised to lose weight before being re- considered (14) . However, accumulating evidence (including the results presented here) suggest that obesity is not associated with poor long-term clinical outcomes (36 -38) . Moreover, low BMI or low serum creatinine as a surrogate of low muscle mass and their decreases over time are associated with increased death risk in transplant waitlisted dialyzed patients (21) . Because healthier (obese or nonobese) MHD patients are usually preferred for transplantation, our data may be confounded by this selection bias. In MHD patients, lower BMI is associated with higher mortality (39) . In our MHD patient cohort, high BMI was not associated with unfavorable posttransplant outcomes. Hence, if our findings can be confirmed by other studies, high BMI should not be a contraindication of transplantation. Nevertheless, the study presented here is unable to examine the question as to whether weight loss before transplantation improves mortality risk or not, although recently it has been suggested that weight change before transplantation had no favorable effect on survival or graft loss (7) . Clearly, prospective studies assessing the effect of pretransplant weight loss strategies on long-term outcomes after kidney transplantation are needed. BMI per se may not be an appropriate measure to characterize nutritional status, body composition, obesity, or muscle mass in dialysis patients (16, 17, 40, 41) . To better characterize nutritional status, additional parameters such as waist circumference or serum creatinine can be used (17,19 -22) . It has been suggested that serum creatinine may better reflect muscle mass under steady-state conditions than BMI (17,19 -22) . Our findings pertaining to muscle mass are in agreement with some previous studies. Oterdoom et al. found that higher muscle mass, assessed by 24-hour urine creatinine excretion, is associated with better survival after kidney transplantation (42) . In dialysis patients low serum creatinine is a marker for protein-energy wasting (43) , which is a strong predictor of mortality (44, 45) and anemia (46) in renal transplant recipients. To the best of our knowledge, no prior study has examined the effect of pretransplant serum creatinine in MHD patients on outcomes after kidney transplantation. Our results suggest that greater or lesser pretransplant muscle mass has a favorable or unfavorable effect on posttransplant outcome, respectively. It is currently not known if improving nutritional status, including increasing BMI and muscle mass before kidney transplantation, improves outcomes. Further studies are needed to answer this question.
Obesity (BMI Ͼ 30 kg/m 2 ) showed a nonsignificant trend toward higher graft-rejection rates in our study (Figure 2B) . Bosma et al. reported that higher BMI is independently associated with higher GFR and filtration fraction 1 year after transplantation, suggesting the presence of glomerular hyperfiltration with altered afferent-efferent balance (47) , which may have played a role in the higher registered rejection rates seen in our study. Further studies are needed to confirm this observation.
Our study is notable for its large sample size, and several important pre-and posttransplant covariates were accounted for in the multivariate analyses. However, like all observational studies, ours too cannot prove causality. Repeated posttransplant measures of weight and creatinine as well as immunosuppressive and other regimens were not available in the SRTR database, but in the full model we did adjust for several transplant-related variables. Patients who were excluded from analyses were likely different from the included ones, but their proportion was relatively small. The variables we used as surrogates for body composition (BMI and serum creatinine) are clearly not ideal. Our study cannot differentiate between intentional and spontaneous weight loss. We are not aware of the potential reasons for weight change, including intercurrent illness or weight-losing interventions such as diet, exercise, or weight loss medication. However, quick and uncontrolled interventions to alter BMI often transiently affect weight (7).
In conclusion, in our large and contemporary national database of over 10,000 renal transplant recipients, pretransplant low BMI showed a trend toward higher posttransplant mortality, and lower pretransplant serum creatinine level, a potential surrogate of sarcopenia, was associated with the unfavorable posttransplant outcomes. These findings may have important implications in providing medical care to tens of thousands of renal transplant waitlisted patients. Additional studies are needed to better understand the association between obesity, muscle mass, and other body compositions and transplant outcomes. Until then, we caution against categorical recommendation of weight loss to apparently obese dialysis patients as a requirement for transplant waitlisting. 
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